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Review article

Awareness and willingness to use HIV pre-exposure
prophylaxis among men who have sex with men in
low- and middle-income countries: a systematic review
and meta-analysis
Siyan Yi§1,2, Sovannary Tuot1, Grace W Mwai3, Chanrith Ngin1, Kolab Chhim1, Khoundyla Pal1,
Ewemade Igbinedion4, Paula Holland5, Sok Chamreun Choub1 and Gitau Mburu5
§
Corresponding author: Siyan Yi, KHANA Center for Population Health Research, No. 33, Street 71, Tonle Bassac, Chamkar Mon, Phnom Penh, Cambodia. Tel:
+855-23-211-505. (siyan@doctor.com)

Abstract
Introduction: To facilitate provision of pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMIC), a better
understanding of potential demand and user preferences is required. This review assessed awareness and willingness to use
oral PrEP among men who have sex with men (MSM) in LMIC.
Methods: Electronic literature search of Cochrane library, Embase, PubMed, PsychINFO, CINHAL, Web of Science, and Google
Scholar was conducted between July and September 2016. Reference lists of relevant studies were searched, and three
authors contacted for additional data. Non-peer reviewed publications were excluded. Studies were screened for inclusion,
and relevant data abstracted, assessed for bias, and synthesized.
Results: In total, 2186 records were identified, of which 23 studies involving 14,040 MSM from LMIC were included. The
proportion of MSM who were aware of PrEP was low at 29.7% (95% CI: 16.9–44.3). However, the proportion willing to use
PrEP was higher, at 64.4% (95% CI: 53.3–74.8). Proportions of MSM aware of PrEP was <50% in 11 studies and 50–70% in 3
studies, while willingness to use PrEP was <50% in 6 studies, 50–70% in 9 studies, and over 80% in 5 studies. Several factors
affected willingness to use PrEP. At the individual domain, poor knowledge of PrEP, doubts about its effectiveness, fear of
side effects, low perception of HIV risk, and the need to adhere or take medicines frequently reduced willingness to use PrEP,
while PrEP education and motivation to maintain good health were facilitators of potential use. Demographic factors
(education, age, and migration) influenced both awareness and willingness to use PrEP, but their effects were not consistent
across studies. At the social domain, anticipated stigma from peers, partners, and family members related to sexual
orientation, PrEP, or HIV status were barriers to potential use of PrEP, while partner, peer, and family support were
facilitators of potential use. At the structural domain, concerns regarding attitudes of healthcare providers, quality assurance,
data protection, and cost were determinants of potential use.
Conclusions: This review found that despite low levels of awareness of PrEP, MSM in LMIC are willing to use it if they are
supported appropriately to deal with a range of individual, social, and structural barriers.
Keywords: HIV; pre-exposure prophylaxis (PrEP); men who have sex with men (MSM); low and middle income countries;
systematic review
To access the supplementary material to this article please see Supplementary Files under Article Tools online.
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Introduction
Human immunodeficiency virus (HIV) is a leading cause of
the global burden of disease [1] and mortality [2].
Currently, 36.7 million people are living with HIV globally,
and on average, 1.1 million people die from it annually [3].
Although significant progress has been made in increasing
access to antiretroviral therapy [2,3], world-wide incidence
of HIV has remained above two million cases annually over

the last decade [3], suggesting that additional HIV prevention interventions are required.
HIV pre-exposure prophylaxis (PrEP) is the provision of antiretroviral (ARV) drugs to HIV-uninfected people at high risk
before potential exposure, to block the acquisition of HIV
[4,5]. In randomized clinical trials (RCTs) conducted in high-,
middle-, and low-income countries, PrEP reduced the risk of
HIV acquisition by 44% among men who have sex with men
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(MSM) and transgender (TG) populations [6], 48% among people who inject drugs [7], and 67% among heterosexual serodiscordant couples [8]. In recent RCTs conducted in the UK and
France, PrEP reduced the risk of HIV acquisition by 86% among
MSM [9,10]. In all these studies and their open-label extensions, significantly higher levels of protection from HIV were
experienced by participants who were adherent to PrEP [11].
The World Health Organization (WHO) recommended the
use of daily oral PrEP to reduce HIV acquisition by HIVnegative partners within serodiscordant heterosexual couples in 2012 [4]. In 2015, WHO expanded the recommendation to include MSM and people who inject drugs [5]. WHO
recommends PrEP to be used as part of a package of
combination prevention interventions [5] that includes HIV
testing, condom use, as well as screening and treatment of
sexually transmitted infections (STIs) [4].
Following these recommendations, studies [12,13] and
reviews [14,15] exploring awareness, willingness to use, and
acceptability of PrEP among MSM have started to emerge
over the last few years. However, these recent reviews have
been broad in scope, and have included data from highincome countries. In his review, Holt [14] focused on acceptability of PrEP and use of ARV treatment as prevention among
MSM in the Americas and Asia pacific, while Young and
McDaid [15] focused on global acceptability of PrEP among
all populations. While both reviews found that PrEP and
treatment as prevention are reasonably acceptable, the
over-representation of studies from high-income countries in
both reviews, as well as the mixed populations in Young and
McDaid’s review [15], limits the extent to which the findings
may be applicable to MSM in low- and middle-income counties, where implementation of PrEP has been relatively limited
compared to high-income countries [15,16].
In addition, Young and McDaid’s review [15] highlighted an
urgent need to better understand motivations for willingness to
use PrEP beyond clinical trials. Such information will inform
practical ways in which MSM and other potential users can be
best supported to access and utilize PrEP, particularly in low-and
middle-income countries where experience with PrEP is limited.
To respond to these information needs, we sought to examine
the awareness of and factors associated with willingness to use
oral PrEP among MSM in low-and middle-income countries.

Methods
This review was conducted in accordance with the preferred reporting items for systematic review and metaanalyses [17] and protocols [18]. The protocol was registered in PROSPERO (ID: CRD42016043994) and the PRISMA
checklist is appended as supplemental file 1.

search string utilized a combination of relevant keywords
and was adapted for use with each database, using Boolean
operators, truncations, proximity operators, and Medical
Subject Heading (MeSH), as appropriate. An illustrative
search used in PubMed is shown in supplemental file 2.
To identify additional relevant citations, reference lists of
included papers as well as “cited by” and “related citation”
tools in Google Scholar and PubMed, respectively, were
used. Three authors of ongoing studies and abstracts
were contacted for information regarding additional data
and peer-reviewed publications. No other limits were
applied.

Inclusion and exclusion criteria
Study design
All study designs, including quantitative and qualitative studies,
were considered eligible. Qualitative evidence regarding participants’ perspectives was included to provide a context for
quantitative findings [19]. Non-original research, secondary
reports, commentaries, editorials, and reviews were excluded.
Domain
Studies were included if they were related to oral PrEP for
HIV prevention. Studies that did not report findings related
to PrEP were excluded.
Population
Studies were included if they reported data generated from
HIV-negative MSM in LMIC, regardless of age. Studies that
reported data from MSM together with other populations
such as TG or sex workers were included, but only data
related to MSM were considered and abstracted.
Intervention
The review included studies that reported awareness or
willingness to use PrEP. Studies that involved actual provision of PrEP and reported acceptability, such as clinical
trials and open-label extensions of trials, were not the
focus of this study and were excluded (Figure 1).

Awareness and knowledge of
pre-exposure prophylaxis
Focus of this review
Theoretical willingness to use if it
were made available

Search strategy
Between July and September 2016, a search was conducted
in Cochrane library, Embase, PubMed, PsychINFO, CINHAL,
Web of Science, and Google Scholar to identify relevant
peer-reviewed articles related to awareness and willingness
to use PrEP among MSM in low-and middle-income countries. Non-peer reviewed literature was not included. The

Actual provision and utilisation of
pre-exposure prophylaxis in trials
or open label extensions
Figure 1. Scope of this review.
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Comparator
As this was a descriptive review, studies were included
regardless of whether they reported outcomes from a control or counterfactual arm.
Outcomes
Relevant patient-related primary outcomes included awareness of and willingness to use oral PrEP as shown in Table 1
below. The review elaborated on factors affecting the
potential willingness to use PrEP where these were provided in the included studies, and mapped these factors
across individual, social, and structural contexts of the
socio-ecological model. The socio-ecological model is
based on the assumption that individual health is determined by factors that are located within an individual, as
well as those in their environment [20]. The model has
been employed by other scholars to map the location of
factors that affect health service utilization [21,22].

Study selection, and data abstraction and
management
Using End-Note software version 7 (http://endnote.com/), all
citations were imported and duplicates removed. Three review
team members independently screened references in two
stages. In the first stage, titles and abstracts were screened to
exclude ineligible studies based on relevance. In the second
stage, full-text versions of selected papers were assessed independently by three reviewers to ensure that inclusion criteria
were met. At each stage, selected papers were compared
between the three reviewers for concordance. Screening and
selection of studies were facilitated by the creation of appropriately labelled sub-folders in EndNote. In the event of uncertainty or disagreement, the three reviewers conferred and
discussed with each other to reach a consensus. Data were
abstracted into a standardized form with the following fields:
authors, year of publication, country of study, design, settings,
study populations, outcomes and limitations. To aid conceptual
understanding of qualitative findings, typical participant quotes
relating to awareness or willingness to use PrEP were also
abstracted. A translator was utilized to translate three
Chinese abstracts and the corresponding full papers which
were subsequently included in the review.

Data analyses
All available data were pooled and synthesized using a combination of a meta-analysis and narrative synthesis approach. The
latter uses descriptive words and texts to summarize and

explain results from a review [23]. For quantitative studies,
proportions of participants who were aware or willing to use
PrEP were abstracted and reported. A synthesis of factors
determining willingness to use PrEP was performed, and
these were classified as being individual, social, or structural
in nature. Qualitative data were drawn on to provide context
for the quantitative findings as recommended [19,24], by identifying participant perspectives about factors that may affect
awareness and willingness to use PrEP among MSM. Using
thematic analysis [25–27], relevant quotes were abstracted,
sorted, compared, and categorized to construct a set of emerging descriptive themes. Themes were then used to populate a
conceptual framework [28] of willingness to use PrEP at the
individual, social, and structural domains. In keeping with the
review protocol, meta-analyses were performed on the primary quantitative outcomes using a random effects model for
pooling proportions [29], but pooled results from fixed effects
models were displayed in graphical outputs to aid comparison
and discussion. Subgroup analyses were not performed.

Bias assessment
Three reviewers evaluated the risk of different types of
biases, including selection bias, attrition bias, and information and reporting bias using methodology suggested in the
Cochrane Collaboration’s tool for assessing risk of bias [30].
Studies were included regardless of risk of bias, but the
impact of their inclusion on the robustness of findings and
conclusions was discussed.

Results
Study selection
This review involved a total of 2186 records. The initial
screening excluded duplicates (n = 733) and studies that
did not specifically focus on PrEP (n = 1238), leaving a
total of 213 citations. Subsequently, 192 citations were
excluded after screening the abstracts and full papers. A
few papers focusing on other populations (e.g. heterosexual couples, sex workers, and TG populations) had
been identified through the search and were excluded
(n = 9). Additional exclusions were due to a variety of
reasons, including poor relevance of outcomes (e.g. cost
effectiveness; n = 118), failure to segregate results by
population (n = 13), and for being reviews (n = 7) or nonpeer reviewed articles (n = 45). In total, 2161 records
from the initial search were rejected for failing to meet
the inclusion criteria. An additional two Chinese citations
were identified from reference lists of included papers.

Table 1. Primary and secondary outcomes of this review
Outcome level

Definition

Awareness of PrEP
Willingness to use PrEP

Proportion of MSM participants who reported knowing about PrEP
Proportion of MSM participants who reported being willing to use PrEP if it was available

Factors affecting willingness to use PrEP

Individual, social, or structural factors that may determine the potential future use of PrEP
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Three authors were contacted to provide full papers or
additional data to that reported in their abstracts, but
these papers were not additional as they had been identified in the original search. In accordance with PRISMA
guidelines for a systematic review [17], a flow diagram
illustrating the literature search, article selection, and
final included studies is shown below (Figure 2).

Methods and study designs of included studies
We included 23 studies published between 2011 and
2016, and involving 15,014 MSM, of whom 14,040 were
from LMIC. Of these, three were published in Chinese, and
the rest were in English. Of the included studies, 19 were
quantitative, two were qualitative, and two were mixed
methods. These 23 studies related to 22 distinct populations. Two Malaysian studies conducted by Lim et al. [31]
and Bourne et al. [32] were linked in that participants of
the quantitative study were invited to participate in follow-on qualitative interviews. All of the quantitative studies were cross-sectional surveys. The study by Wheelock
et al. [33] was a replication of that by Eisingerich et al.
[34], but in a different country. The following tables present the key characteristics of the quantitative (Table 2)
mixed-methods (Table 3) and qualitative studies (Table 4)
included in the review.

Total database search (n=2184):
CINAHL (n=42)
Embase (n=385)
Pubmed (n=254)
PsychINFO (n=95)
Google Scholar (n=997)
Web of Science (n=344)
Cochrane Library (n=67)
Excluded (n=1,971):
Not focussed on PrEP (n=1238)
Duplicates (n=733)

Records after initial screening (n=213)

Excluded (n=192):
Focussed on populations other
than MSM (n=9)
Focussed on other outcomes
(n=118)
Did not segregate MSM results
(n=13)
Reviews and non-peer reviewed
articles (n=52)

Additional citations from reference list
search (n=2, Chinese)

Included articles (n=23)

Figure 2. Study selection.

Recruitment and data collection settings
Most studies were conducted in urban areas. Five studies
used internet-based advertisement and recruitment, including Facebook or organizational websites [31,35,38], often in
combination with mobile-based social dating applications
(such as Grindr) [31] as well as TV and newspaper advertisements [38]. Several studies used face-to-face recruitment, exclusively or in combination with online methods.
Five studies sampled participants from service provision
sites such as community-based and youth-led non-governmental organizations [31,32,50,52]. Two studies utilized
health facilities for recruitment and data collection, including community health clinics [53] and HIV voluntary counselling and testing sites [51]. Three studies utilized other
venues frequented by MSM such as entertainment venues
[33,47], gay community events [53], and beauty salons [50].
Other sites of recruitment included parks, volley-ball courts,
and streets [50].

Geographical location of included studies
Two studies conducted by Ayala et al. [35] and Eisingerich
et al. [34] were multi-country in scope, while all the rest
were conducted in a single country. The 21 single-country
studies had MSM participants from Brazil, China, India,
Kenya, Malaysia, Myanmar, Peru, Thailand, Uganda,
Vietnam, and South Africa. China contributed to most studies (n = 8), followed by Peru (n = 3), and Thailand (n = 3).
The study by Ayala et al. [35] was conducted in 145 countries, which included high-income countries as highlighted
in Table 2. At the time of the review, almost all of the
countries from which the participants in this review were
based were classified by the World Bank as either middleor upper-middle income, except Uganda which was a lowincome country (http://data.worldbank.org/country).

Description of participants in the included
studies
Together, the included studies involved a total of 15,014
MSM. Of these 14,040 were from LMIC. (some few TG
participants may be included where they were not separated from MSM in two papers). The profile of MSM
included in the studies within the review included homosexual and bisexual MSM. In total, eight studies from Brazil
[39], China [46,47,49], and Kenya [51] included participants
who described themselves as bisexual. The proportion of
participants that were bisexual was highest in the Kenyan
study by Karuga et al. [51] at 50.1%. Several studies
included MSM who were sex workers. In Karuga et al.
[51], 11.8% of participants were sex workers, while,
Oldenburg et al. [41] purposely recruited an exclusive sample of MSM sex workers.
Apart from MSM, several studies included other populations, although only data related to MSM were abstracted.
For example, Galea et al. [50] focused on MSM, female sex
workers, and TG populations in Peru. In their study,
Eisingerich et al. [34] included intravenous drug users,
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setting

Country and

2016

Draper et al.,

Ding et al.,2016

Participants’
Factors associated with willingness to use

19.1% willing to use PrEP.

outness (β: −0.15; 95% CI= −0.18 to −0.12, p<0.001), and
knowledge about PrEP (β: −0.14; 95% CI= −0.18 to −0.10,

aware.α

80.8% were willing to use PrEP. α PrEP stigma (β: −0.51; 95% CI= −0.55 to −0.48, p<0.001),

Willingness to use

respondents were

69.8% of the

Awareness

willingness to use it.
Willingness to use PrEP was associated with reporting never/

(AOR:0.35; 95% CI=0.21–0.59).

due to long-term use were less likely to be willing to use it

months. Those reporting concerns about PrEP side-effects

partners (AOR:2.25; 95% CI=1.23–4.11) in the past three

casual partners (AOR:2.05; 95% CI=1.06–3.99) or no casual

partners (AOR:2.05; 95% CI=1.10–3.67) or more than five

regular partner (AOR=2.94; 95% CI=1.41–6.14) or no regular

(AOR:1.82; 95% CI=1.10–3.02), having had more than one

CI=1.05-3.03), perceiving as likely to become HIV positive

95% CI=1.00–4.10), residence Mandalay (AOR:1.79; 95%

used, with casual partners (adjusted odds ratio (AOR: 2.02;

62% were willing to use PrEP

occasional use of condoms compared to always/mostly

5% aware.

undiagnosed GMT.

Not reported.

identity, and marital status were not associated with

CI=0.47–0.97, p=0.034). Education, occupation, gay sexual

significantly less willing to use PrEP (AOR:0.68; 95%

2.17, p=0.02). Condom use at last anal sex with man were

sex partners in the past 6 months (AOR:1.53; 95% CI=1.07–

AOR: 1.69; 95% CI=1.16–2.45, p=0.026), two or more male

among 434 HIV

434 GMTβ

Interval (CI)=1.13–4.23, p=0.006), immigration to Shanghai
(21.5% among immigrants vs 15.9% among local residents;

years (Adjusted Odds Ratio (AOR):2.18; 95% (Confidence

already using PrEP.

Myanmar.

Survey.

from LMIC.
Willingness to use PrEP was associated with older age (≥ 45

gay and 2.5% were

Not reported.

Mandalay in

Yangon and

China.

Shanghai,

countries reported lower acceptability of PrEP than those

CI=0.02–0.23, p=0.021). Respondents in high-income

having experienced service provider stigma (β: 0.12; 95%

PrEP. Acceptability of PrEP was positively correlated with

76% self- identified as

years.

Age range was 12–90

characteristics

p<0.001) were negatively correlated with acceptability of

1,033 MSM.

2774 MSM.α

Sample size

America.

Survey.

Online survey.

Design

Latin

Europe and

Africa, Asia,

Ayala et al., 2013 145 countries-

Author, year

Table 2. Characteristics and findings of quantitative studies included in the systematic review
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setting

Country and

Brazil.

Hoagland et al.,

2016

China.

South Africa.

He et al., 2014

2012

Eisingerich et al., Peru, India,

Author, year

Table2. (Continued)

study.

Cross-sectional

Survey.

Survey

Design

Participants’

with regular HIV testing.

if they had to pay for it.

vs 65.4%; p=0.40). 75.8 % reported they would use PrEP even

(62.7% vs 46.8%; p=0.99), or failure to perform a test (62.7%

p=0.16), a negative compared to a positive HIV test result

male gender compared to transgender (81.8% vs 89.3%;

84.1%; p=0.35). Willingness to use was not associated with

81.7%; p=0.85) and among those aged ≥36years (81.02% vs

PrEP increased marginally among 25–35year olds (81.02%, vs

Compared with those aged 18–24 years, willingness to use

p=0.02). Willingness to use PrEP was not associated with age.

last 12 months compared to those without (68.8% vs 60.2%;

schooling; p=0.006), and those with a recent STD diagnosis in

those with <12 years vs 84.5% among those with ≥12 years of

among those with more years of schooling (78.1% among

82.1% were willing to use PrEP. Willingness to use PrEP was higher among those aware of PrEP

get the information quickly and easily.

promoted through media to make sure MSM in China can

reported that information regarding PrEP should be

Factors affecting use were not reported; however, the study

compared to those unaware of it (85.4% vs 76.9% ;p<0.001),

61.3% were aware.

Not reported.

having to use condoms, and 55–88% were willing to use it

positive.

Median age=29 years

1131 MSMε

heard of PrEP.

Overall, 31.4% had

use PrEP despite side effects; 39–88% were willing to use it
despite having to pay, 32–85% were willing to use it even if

46.8% were HIV

Mean age=28 years.

buttocks while South African MSM preferred daily pill to arm

Africaβ.

were aged ≥41 years.

injection. Of those willing to use PrEP, 32–72% were willing to

Indian and Peruvian MSM preferred bimonthly injection in the

across India, Peru and South

8% reported that PrEP would be “very embarrassing” to take.

42–69% reported that PrEP would give them “a lot of hope”. 3–

Factors associated with willingness to use

aged 16-24, and 6%

69% reported ‘yes, definitely’

Willingness to use

and 25% ‘yes, probably’

Not reported

Awareness

reported; 39% were

Mean age of MSM not

characteristics

1323 MSMδ

383 MSMγ

Sample size
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Ko et al., 2016

2012

Jackson et al.,

Author, year

Taiwan.

1151 MSM

44.4% were willing to take PrEP even if it was not 100%
effective, and only 23% were willing to self-pay Taiwan $
340 for PrEP. Willingness to use PrEP increased with tertiary
compared with secondary education (30.7% vs 2.2%;
p<0.05), and among those with professional qualification
(54.8% vs 12.2%; p<0.05), and a past history of receiving

(48.5%), had
professional
qualification (61.2%)
and were employed
(57.0%).

were not.

participants who were willing to use PrEP and those who

There was no difference in age or employment between

HIV non-occupational PEP (5.9% vs 3.2%; p value <0.01).

prevent getting HIV, 43.7% were willing to take a pill daily,

from the north

Of those willing to use PrEP, 70% were willing to take pills

PrEP was a facilitators of potential use.

of PrEP was a potential barrier, while perceived benefits of

STI were not associated with willingness to use PrEP. Stigma

or more. Occupational status and previous experience of

1,000 Yuan or less vs 2.8% among those earning 5,000 Yuan

monthly personal income (37.9% among those earning

undergraduate or higher education; p<0.001), lower

38.2% high school vs 49.3% among those with

among primary school, vs 10.3% among middle school, vs

than rural residence, higher education attainment (2.2%

Willingness to use PrEP was associated with urban compared

Factors associated with willingness to use

before and after sex, 61% were willing to take PrEP to

56% were willing to use PrEP.

lower willingness to use it.

use PrEP, while 22.8% had

63% had high willingness to

Willingness to use

years, most were

Not reported

Not reported.

Awareness

age range=18–53

Mean age=25.9 years,

were urban dwellers.

China.

Mean age=27.6 years;

years, and 76.8%

Online survey.

Participants’
characteristics

Chongqing,

570 MSM

Sample size

age range=18–62

Survey.

Design

Sichuan and

Guangxi,

setting

Country and

Table2. (Continued)
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Malaysia.

Kualar Lumpur,

setting

Country and

Wei et al., 2011

2013

Sineath et al.,

2013

Peinado et al.,

2016

Participants’

status, or income. A third (35.6%) were willing to pay for
PrEP. However, of these the majority (88.3%) were not
willing to spend over 200 RM (USD 50) on PrEP per month.
Of the 603 participants who reported not willing to use

education and 85.2%
were in part-time or
full time employment.

face).

Guangxi, China. Survey (face to

Thailand.

Survey (online)

analysis).

Pucallpa,

Peru.

(secondary

and

Survey

650 MSM.

404 MSM.φ

532 MSM and TGι

Mean age=28 years

about PrEP.

19.7% had heard

PrEP.

Mean age was=25 years. 7% were aware of

range 16–68 years.

Median age=28 years;

condoms were more effective than PrEP.

the doctor every three months”. In addition, 35% believed

take medication every day” and 28% “didn’t want to go see

willing to pay for it. Overall, 34% “didn’t want to have to

Of those willing to use PrEP 65% indicated they would be

to use oral PrEP.

versatile, were independently associated with acceptability

if free and safe.

willingness to use.

91.9% were willing to use PrEP Side effects and efficacy of PrEP were reported as influencing

PrEP was described.

36% were willing to use after

p=0.01) and exclusively receptive (AOR:7.5; 95% CI=1.653.2, p=0.01) during anal intercourse, compared to being

receptive most of the time (AOR: 9.1; 95% CI=1.8–46.5,

willing to use rectal PrEP

After adjustment for age, city, and education, only being

PrEP while 91.7% were

96.2% were willing to use oral

willingness to use (AOR: 2.28; 95% CI=1.25–4.14, p<0.05).

Lima, Iquitos

with Peer Health Educators was associated with higher

27.7% preferred a PrEP lubricant to a pill. Previous contact

years.

daily.η

95.4% were willing to use PrEP Overall, 56.7% willing to take PrEP given side effects, and

PrEP (11.4%).

they always use a condom and therefore would not need

them (5.8%), failure to afford PrEP (8.8%), or the fact that

medication (8.3%), or what other people might think of

that PrEP won’t work (9.8%), worry about forgetting to take

were aged 15–19
Not reported.

age, residence in Kuala Lumpur, education, employment

post-secondary

Not reported.

p<0.001). Willingness to use PrEP was not associated with

addition, 87.2% had

93.7% were HIV

(32.7%), Indian (32.8%) and mixed and other races (36.7%;

aged <25 years. In

PrEP, the reasons offered were side effects (18.6%), fear

more likely to use PrEP (48.6%) compared to Chinese

Overall 19.6% were

with high likelihood to use compared to those with no such

Recent STI diagnosis in the past 12 months was associated

Factors associated with willingness to use

diagnosis (43.3% vs 36.1%; p=0.003). Malay participants

39% were willing to use PrEP.

Willingness to use

Age range=16–68.

PrEP.

44% were aware of

Awareness

16.6% as bisexual.

homosexual and

80.4% self-identified as

characteristics

Vietnam.

300 MSMγ

990 MSMϕ

Sample size

negative, and 27%

Survey.

Survey (online).

Design

city,

Oldenburg et al., Ho Chi Minh

Lim et al., 2016

Author, year

Table2. (Continued)
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Xue et al. 2015

Xia et al., 2016

2013

Wheelock et al.,

Author, year

China.

Survey (online).

760 MSMκ

willingness to use PrEP compared to those who heard

between 2001–5000

72.8% aware of, or
fully understood
PrEP.

77.2% self-identified as
homosexual and 20%
remainder as bisexual

not happening daily (59%).

medication (68.7%), and reporting that risk behaviors were

(38.3%), cost (28.7%), inconvenience of taking daily

(41.6%), the perception that PrEP is not 100% effective

risk assessment (54.2%), privacy and confidentiality

willingness to use PrEP were: side effects (60.8%), low self-

that were identified by participants as preventing

32.1% would possibly use PrEP. 61% (305/500) would possibly take PrEP orally daily. Factors

of residency in the city.

p=0.065). Men using the internet were more likely to report

51.1% earned

an STI in the last year.

not diagnosed, though not significant (67.6% vs 72.6%;

were employed,

about PrEP face-to-face (75.2% vs 66.4%; p<0.05).

diagnosed with an STI in last 12 months compared to those

to college level, 61.4%

Willingness to use was not associated with age or duration

63.4%; p=0.007) but was inversely associated with being

73% were educated

been diagnosed with

the last 12 months compared to those that didn’t (76% vs.

16.2% as bisexual.

RMB and 7% had

participants (71.1%) or /other/unsure (38.5%; p=0.017).
Willingness to use was associated with taking an STI test in

identified as gay, and

Bisexual (77.2%) were more likely to use it compared to gay

53.5% were aged 25–
34 years. 81.1% self-

versus 67.5% of unmarried/divorced or widowed (p=0.001).

aged 18–24 and

84.4% of those married/cohabiting were willing to use PrEP

62; years. 31.7% were

Willingness to use PrEP was associated with marital status:

were ‘definitely’ and 56.5% ‘probably’ willing to use PrEP.

education.
71.3% willing to use.

the arm. After learning of potential mild side effects, 24.6%

had post-secondary

Mean age=28; range 18– 19.1% aware.

would be ‘fairly embarrassing’. Daily pill was the preferred
route of administration followed by a monthly injection in

least 16 years. 94%

China.

487 MSM

would be ‘very embarrassing’ and 5.8% reported that it

participants were at

were ‘probably’ willing to use PrEP despite having to pay
500 Baht a month for it. 2.7% reported that taking PrEP

‘probably’ use PrEP.

Of those willing to use PrEP, 58.8% were ‘definitely’ while 35%

Factors associated with willingness to use

‘definitely’ and 49.2% would

39.2% reported they would

Willingness to use

Shanghai,

Wuhan and

Awareness

4% and 54% were 16–18 Not reported.

respectively. Eligible

Survey.

Participants’
characteristics

Thailand.

260 MSM.

Sample size

and 19–24 years,

Survey.

Design

Chiang Mai,

Bangkok and

setting

Country and

Table2. (Continued)
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setting

Country and

2013

Zhang et al.,

Participants’

STIs (OR 3.78, 95% CI=1.42–10.47, p<0.01); age 25 years or

37% were willing to use it if it had to be taken once daily or
a weekly respectively. Willingness to use PrEP was
associated with lower education up to middle school
compared to those with college education and above
(68.4% vs 59.5%; p=<0.001), married marital status
compared to never married (69.7% vs 62.4%; p=0.035);

(75.1%) resided in
urban areas. 70% selfidentified as
homosexual and 21%
as bisexual.

or sexual identity.

Willingness to use was not associated with age or residence

or sometimes found sexual partners on the internet.

use PrEP compared with higher risk participants, who often

partners on the internet were more likely to be willing to

p=0.027). Participants who did not or rarely found sexual

compared to those without STI history (71.9% vs 62.6%;

monthly income of >3000 (p=0.109); and STI history

earnings of <1000; (p=0.013) but not compared to high

moderate (1000-3000) monthly income (compared to lower

by people known to participants. However, only 30% and

the sample. Majority

be made free, and to 77% if it were free and had been used

China.

safe and effective.

64% were willing to use PrEP if Proportion willing to use PrEP increased to 71% if it were to

1.19, p=0.08)

insertive or versatile positioning (OR:0.47; 95% CI=0.17–

CI=0.89–4.29, p=0.07) or receptive anal sex positioning vs.

of HIV testing vs. no history of HIV testing (OR:1.95; 95%

willingness to use was not associated with a lifetime history

confident” (OR:2.63; 95%CI=1.12–6.24, p=0.01). In contrast,

daily, oral medicines for 1 year vs. not being “very

p=0.02); and being “very confident” in the ability to take

older vs. age less than 25 years (OR:2.30; 95% CI=1.10–4.79,

comprised 41.5% of

PrEP

CI=1.12–7.12, p=0.01); infrequent sex (once per month or
less) vs. two or more sexual encounters per month

gay.

Age range=18–74 years.

regularly planned sex vs. unplanned sex (OR:2.83; 95%

bisexual and 71% as

(OR:2.36; p=0.02); a lifetime history of STIs vs. no history of

one or more partners (OR: 2.25; 95% CI=1.09–5.11, p=0.04);

heterosexual, 16% as

Willingness to use PrEP among MSM was associated with

Factors associated with willingness to use

having zero regular partners in the preceding 6 months vs.

41% willing to use PrEP.ν

Willingness to use

self-identified as

22% were aware of

66% aware of PrEP.

Awareness

18–49 years. 13%

μ

Mean age=23.7; range

characteristics

18–24 years

1402 MSMο

131 MSMλ

Sample size

and Sichuan,

Survey.

Survey.

Design

Guangxi,

Chongqing,

Thailand.

Yang et al., 2012 Chiang Mai,

Author, year

Table2. (Continued)

Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580

10

setting

Country and

Survey.

Design
152 MSMπ

Sample size

Participants’

15.1% as bisexual.

as homosexual and

84.9% self-identified

Age range=18–61 years.

characteristics

PrEP.

11.2% aware of

Awareness

take PrEP if available.

‘definitely’ or ‘probably’

67.8% were willing to

Willingness to use

(26.3%).

drugs (14.5%) or not being able to afford ARV drugs

(20.1%), being refused sex by male partners after using ARV

PrEP (21.7%), being treated as an AIDS patient by people

disruption by PrEP (44.7%), development of resistance from

lack of prevention efficacy in PrEP (44.1%), diet and sleep

Participants expressed worry about side effects (63.8%),

months versus no such diagnosis (88.9% vs 72.4%; p=0.15.

74.7%; p=0.89], or previous diagnosis of STD in the past 6

p=0.47; bisexual orientation versus homosexual (73.7% vs

monthly income (RMB) <2000 versus >2000 (77.1% vs 72%;

non-Beijing residence (63.3% vs 77.1%; p=0.13), lower

[73.1% vs 77.1%; p=0.60), local Beijing residence versus

(single/divorced/ widowed versus married/cohabiting

those with >12 year of education; p=0.09), marital status

education (80% among those with <12 vs 68.1% among

Willingness to use PrEP was not associated with years of

years versus ≥30 years (68.8% vs. 83.9%; p=0.04).

Willingness to use PrEP was associated with young age <30

Factors associated with willingness to use

Total participants in this study were 3748, and were from 145 countries globally, including Asia (26%), Caribbean (2%), Eastern Europe and Central Asia (17%), Latin America 567 (15%), Middle
East and North Africa (2%), Oceania (6%), sub-Saharan Africa (5%), and western and Northern Europe and North America (26%). Awareness and willingness to use data reported here relate to 2774
LMIC participants only; global awareness and willingness to use PrEP were 72% and 82%, respectively.
β
Participants included gay men, other men who have sex with men and transgender participants (GMT). Among 434 of 520 were HIV undiagnosed GMT and 17% (n = 86) were HIV positive.
χ
The overall sample was 1790, which included MSM, FSWs, IDUs in Peru, Ukraine, India, Kenya, Botswana, Uganda, and South Africa. However, MSM (n = 383) were sampled in Peru, India, South
Africa.
δ
1407 MSM were approached, but only 1323 questionnaires completed and analyzed.
ε
The overall sample was 1187 of whom 95.3% were male and 4.7% were transgender participants.
ϕ
A total of 2,644 participants were screened from whom the 990 were included.
γ
This was an exclusive sample of MSM who were also sex workers.
η
Among the 93.7% (n = 281) HIV-negative individuals in the study.
ι
Proportion of MSM vs. TG was not stated.
φ
470 MSM took part in the survey but 404 completed the survey and were included in the analysis.
κ
A total of 887 MSM started to fill questionnaire, but only 760 qualified questionnaires were analyzed.
λ
326 individuals completed the screening questionnaire out of which 238 MSM and TG were eligible and completed the survey (131 MSM and 107 TG)
μ
Mean age reported here is that of MSM participants only.
ν
Willingness reported here is among MSM participants, and excludes transgender participants.
ο
1407 MSM were recruited, but 1402 completed the questionnaires and were analyzed in the study.
π
159 MSM were enrolled, but only 152 used for analysis as 7 were deleted for not having sex with men in the past 6 months.
FSW: female sex worker; GMT: gay, men who have sex with men and transgender; HIV: human immunodeficiency virus; MSM: men who have sex with men; IDU: injecting drug user; PEP: postexposure prophylaxis; Taiwan $: Taiwan dollar; PrEP: pre-exposure prophylaxis; RMB: Ren Min Bi (currency of People’s Republic of China); STI: sexually transmitted infection; STD: sexually
transmitted disease; TG: transgender.

α

Zhou et al., 2012 Beijing, China.

Author, year

Table2. (Continued)
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Lima, Peru

Kisumu, Kenya

Galea et al. [50]

Karuga et al. [51]

Mixed methods.

conjoint analysis)

(FGDs and

Mixed methods

Design

Factors associated with willingness to use

80 MSM

decrease in condom use were concerns for MSM.
Participants preferred PrEP provided at healthcare

various
concerns

(p = 0.616), or university compared to secondary
education (81.2% vs. 89.5%; p = 0.470), or marital

low

interviews.

influencing willingness to use PrEP from qualitative

and a lack of information were reported as

medicines, uncertainty over PrEP effectiveness, cost,

status (p = 0.157). Stigma, general dislike of taking

Willingness to use PrEP was not associated with age

was noted to be

homosexual

to homosexual (96.2% vs. 74.1%; p = 0.025).

available.β

knowledge of PrEP

and 49.1% were exclusively

orientation, being higher among bisexual compared

in-depth

PrEP if made

not reported, but

willing to use

Willingness to use PrEP was associated with sexual

centres as opposed to pharmacies, due to cost.

professionals and a belief that PrEP would result in a

but had

83.3% were

with PrEP use, while mistrust of health-care

using PrEP,

11.8% were sex workers,

Precise proportion

effects, stigma and discrimination were associated

supportive of

68.8% were HIV negative,

Median age = 24.9 years.

of PrEP

Mean age for MSM = 33 years Little or no awareness Participants were High out-of-pocket cost, partial efficacy, and fear of side

use

Willingness to

17 MSM.α

Awareness

Participants’ characteristics

Sample size

β

The overall sample was 45 including 15 FSW, 13 TG, and 17 MSM. Figures for each country were reported separately but have been averaged here.
Willingness reported is among the 55 HIV-negative MSM.
FSW: female sex worker; FGDs: focus group discussions; MSM: men who have sex with men; PrEP: pre-exposure prophylaxis; TG: transgender.

α

Country and setting

Author, year

Table 3. Characteristics and findings of mixed-methods studies included in the systematic review
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Malaysia.

Kuala Lumpur,

Country and
setting

Qualitative

Qualitative

Design

Factors associated with willingness to use

mean
age = 26.1.

were aware

participants

None of the

available

partners, and ability to take PrEP discreetly.

desire to have safe sex with HIV-positive steady

included peace of mind when condoms break/slip,
‘additional protection’ in case condom breaks,

and fear of side effects were barriers. Motivators

sufficient.
55.7% would use PrEP if Stigma, shame, lack of trust, cost of PrEP, fake pills,

relationships as use of condoms would be

PrEP which can’t be seen or felt. Participants felt
that PrEP may not be needed in monogamous

The physical barrier of condoms was preferable to

perceived as having riskier behaviours such as
barebacking or ‘raw sex’ by non-PrEP using peers.

to take PrEP daily, confidentiality and data
protection concerns, fear of stigma and being

potential side effects, anticipated lack of discipline

PrEP were free or cost a maximum of RM 50–200
(USD 12–49) per user per month. Barriers included

concerned about a
range of barriers.

age.

higher number of concurrent sexual partners and if

to use PrEP but

Most MSM were willing Participants would consider PrEP in future if they had

Willingness to use

was
≥18 years of

Not reported.

Awareness

but eligibility

Not reported,

Participants’
characteristics

61 MSM and 10 key 21.3% were
informantsα.
bisexual and

18 MSM.

Sample size

α
Key informants (n = 10) included community leaders and healthcare providers.
MSM: men who have sex with men; PrEP: pre-exposure prophylaxis; RM: Malaysia Ringgit; USD: USA dollar.

Mumbai, India.

Chakrapani et al. [52] Chennai and

Bourne et al. [32]

Author, year

Table 4. Characteristics and findings of qualitative studies included in the systematic review
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serodiscordant couples, and young women in Ukraine,
India, and other African countries. Studies by Peinado
et al. [42], Yang et al. [47], and Hoagland et al. [39] included
MSM and TG populations. These studies segregated the
results by gender identity, and for the purpose of this
review, only data related from MSM in these studies were
considered. However, the 2016 study by Draper et al. [37]
included MSM and TG participants, who were not fully
segregated.
Given the relevance of PrEP for HIV prevention, most
studies included HIV-negative status as an eligibility criterion. However, in the study by Karuga et al. [51], only 68%
were HIV negative, because recruitment involved all MSM
who were presenting for HIV testing, but only HIV-negative
participants were asked about their willingness to use PrEP.
Likewise, 46.8%, 18%, and 17% of initial participants in the
studies by Hoagland et al. [39], Ayala et al. [35], and Draper
et al. [37] were HIV positive, respectively. Similarly, in these
studies, willingness data were generated from HIV-negative
participants. The Thai study by Ding et al. [36] and the
Malaysian study by Lim et al. [31] found that a small proportion of their participants were already using PrEP (2.5% and
<1%, respectively). Finally, the profile of participants was
also influenced by the recruitment strategies of the included
studies, including eligibility criteria. While most studies
recruited MSM older than 18 years, two studies had lower
age eligibility criteria of 15 years [41] or 16 years [33].

Bias assessment
Included studies had multiple sources of bias resulting from
confounding, recruitment, non-response, social desirability,
and attrition bias (supplemental file 3).
Confounding: All of the quantitative studies were crosssectional in design and had high potential for bias and
confounding. All studies reported hypothetical likelihood
of using PrEP, which could change once PrEP is provided.
Recruitment bias: The risk of recruitment bias was significant in a number of studies, based on the methods and
settings where recruitment took place. The study by Ayala
et al. [35] included MSM participants from 145 countries
globally, including Asia (26%), the Caribbean (2%), Eastern
Europe and Central Asia (17%), Latin America (15%), Middle
East and North Africa (2%), Oceania (6%), sub-Saharan
Africa (5%), and western and Northern Europe and North
America (26%). In this study [35], awareness and willingness to use data were segregated by geographic region.
However, overall correlation statistics were not, and therefore participants from high-income settings may affect the
reported correlation statistics. In the Indian study by
Chakrapani et al. [52], participants were recruited exclusively through a community-based organization, an
approach that may have excluded MSM who did not have
contact with community-based HIV services. Sineath et al.
[43] recruited a convenience sample of Thai MSM exclusively through online methods, which excluded those who
did not have access to internet.
The studies by Lim et al. [31], Bourne et al. [32], and
Jackson et al. [53] expanded their online-based recruitment

to include recruitment through local non-governmental
organizations, which may have facilitated inclusion of different profiles of MSM. A number of studies recruited
specifically from sites which were thought to be frequented
by high-risk MSM, including from entertainment venues in
Thailand [33,47], gay community events in China [53], and
beauty salons in Peru [50]. Although appropriate for identifying MSM who require PrEP, these strategies may exclude
other MSM, for example those who are not living openly as
MSM. A number of studies in Thailand [43], Malaysia
[31,32], Kenya [51], and China [46], among others, started
off by recruiting MSM and then screened them for eligibility based on age, HIV status, and availability and interest to
participate in interviews, among other criteria, thereby
limiting generalizability of findings to wider MSM populations. In addition, recruitment from rural areas across all
studies was limited.
Attrition and non-response bias: The studies by Xue et al.
[46], Sineath et al. [43], Zhang et al. [48], and He et al. [38]
reported instances of non-responses or incompletely filled
questionnaires, which introduced response bias and may
limit generalizability.
Social desirability bias: Most of the measures reported in
the included studies were self-reported, and therefore
were prone to social desirability bias, especially selfreported sexual behaviours. Because of a social desire for
positive self-presentation, willingness to use PrEP may have
been over-reported by some participants in Peru who saw
its use as responsible behaviour [50] while it could have
been under-reported by other participants in Malaysia,
India, Peru, and Thailand who thought it may be perceived
it as a sign of promiscuity [32,33,50,52]. The potential for
social desirability bias may have been mitigated by the use
of anonymous online data collection methods in the studies
by Sineath et al. [43], Lim et al. [31], and Ayala et al. [35],
while being particularly accentuated in four studies by
Bourne et al. [32], Chakrapani et al. [52], Karuga et al.
[51], and Galea et al. [50], which involved face-to-face
focus group discussions with peers. The two studies by
Chakrapani et al. [52] and Karuga et al. [51] also involved
in-depth interviews in addition to focus group discussions.
Researcher bias: The four studies that reported qualitative findings lacked clarity around reflexivity. They contained limited documentation of interview dynamics,
emotions, interactions, or beliefs of the researchers as
recommended [54], especially when dealing with sensitive
topics [55]. Although absence of this information may have
been occasioned by word count limitations, it limited our
analysis of the researchers’ influence on the research conduct and reported findings, which is an essential element of
evaluating qualitative research [25].

Description of PrEP
The included studies used consistent definitions of PrEP and
most explored oral PrEP except for the Peruvian study conducted by Peinado et al. [42], which explored both oral and
rectal PrEP. However, findings in this study were segregated
by route of administration. Most studies provided a
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definition of PrEP to participants and emphasized the need
to adhere to medications as part of the definition.
In addition, four studies [33,34,41,50] explored participants’
preferences regarding the most desirable formulations of PrEP,
such as injectable or oral or lubricant forms. However, these
results did not affect the data reported in this review regarding
willingness to use oral PrEP, as data were segregated.
Definitions and general information regarding PrEP were
provided by researchers or data collectors who were facilitating interviews, focus group discussions [32,49,50,52], or
face-to-face quantitative questionnaires [33,34,47]. In other
studies, this information was provided online as part of the
study [31,35]. In one Indian study, explanation of PrEP was
facilitated by pictorial cards [52], while in several other
studies [33,34,49,52], PrEP definitions were provided in
both English and local languages to aid its understanding.
At least three studies [31,32,50] made explicit attempts to
differentiate PrEP from post-exposure prophylaxis (PEP) in
their definitions of PrEP to participants, and in rare cases
[52], data collectors were provided with fact sheets to
respond consistently to participants’ queries.

Nature of outcomes reported
Of the outcomes of interest to this review, the most
reported outcome was willingness to use. All quantitative
studies reported either proportions of participants who
were aware of or willing to use PrEP, or both, with a
number of them examining willingness to use PrEP in different situations related to efficacy, cost, knowledge of
partners, condom use, and stigma [31,33,34,40,41,49].
Two qualitative [32,52] and two mixed-methods studies
[50,51] explored perceptions and perceived barriers and
facilitators of willingness to use PrEP, in relation to relationships, sex, PrEP information and education, cost, ways and
venues to access PrEP, risk perception, ideal nature of PrEP,
perceived effectiveness, side effects, and adherence issues.
Four studies [35,42,47,52] exploring willingness to use
described this outcome as acceptability, even though they
explored theoretical use of PrEP if it were made available.
This information was abstracted and reported as willingness
to use. Because this review excluded trials in which PrEP
was being assessed, it excluded actual acceptability in
which PrEP was provided as part of the study. In one
study by Ding et al. [36], participants were assessed for
willingness to use PrEP and were subsequently offered it.
However, although the study noted the proportion of participants that eventually took up the PrEP (20.5% changed
their minds), this review abstracted the initial willingness to
use data, rather than the acceptance data. Nevertheless, as
noted above, the study by Ding et al. [36] and that by Lim
et al. [31] incidentally found that small proportions of
participants (2.5% and <1%, respectively) were already
accessing and using PrEP at the time of the study.

Awareness of PrEP
Of the 14 studies reporting levels of awareness, 13 provided quantitative proportions of participants who were

aware of PrEP. All studies reporting awareness used a
simple binary question asking participants whether they
were aware (or had heard) of PrEP, which was a consistent
measure of awareness across studies. Most studies that
explored awareness found a lack of awareness of PrEP
among participants. With the exception of four studies by
Hoagland et al. in Brazil [39], Yang et al. in Thailand [47],
Ayala et al. [35], and Xue et al. in China [46] that reported
awareness of 61.3%, 66.0%, 69.8%, and 72.8% respectively,
most studies reported much lower awareness of PrEP ranging from 5.0% in Myanmar [37], 7.0% in Thailand [43],
11.2% in China [49], 19.1%, 19.7%, 22%, and 31.4% in China
[38,44,45,48], and 44.0% in Malaysia [31]. In the Peruvian
study by Galea et al. [50], participants had little or no
awareness of PrEP. In addition, the Indian study by
Chakrapani et al. [52] reported that none of the participants in their study were aware of PrEP prior to the study.
The proportions were highly heterogeneous (Q statistic = 2898, I2 = 99.5; (95% CI: 99.5–99.6), p < 0.001).
Meta-analysis of the 13 studies that reported quantitative
data of proportions of MSM who were aware of PrEP found
that the pooled estimate of awareness among MSM was
29.7% (95% CI: 16.9–44.3) (Figure 3).
Besides overall awareness, few studies explored factors
that were associated with awareness of PrEP. Older age in
Brazil [39], more years of education in Brazil and Thailand
[39,43], urban residence in China [45], frequent use of
internet as a source of information in China [45], employment in Thailand [43], and non-local ethnicity in Thailand
[43] were associated with higher levels of awareness. Two
studies from Brazil [39] and China [45] reported conflicting
results regarding the association between PrEP awareness
and gender identity (gay versus TG or bisexual) or a recent
STI diagnosis. Marital status was not associated with PrEP
awareness in China [45].
However, the reported awareness did not necessarily
reflect an accurate understanding of PrEP. Three studies
checked whether the self-reported understanding of PrEP
was accurate. In India, four participants who initially
reported that they had heard of PrEP were later found to
have mistaken PEP for PrEP [52]. In a Chinese study by Xia
et al. [45], 19.1% of participants were aware of PrEP.
However, when their self-reported understanding of PrEP
was assessed, only around half of them (9.5%) had what
could be considered an accurate understanding. Two studies [35,46] made a distinction between participants who
were aware of the basics and those who fully understood
PrEP and found that roughly half of participants who
reported being aware of it had just a basic understanding.
In addition, some studies [33,34,50,52] provided information and definitions of PrEP before the assessment of
awareness while others [32,49] defined it after assessment
of awareness but before assessment of willingness to use it,
which may have introduced varying potential for recall bias.
This was compounded by the fact that participants had
opportunities to ask clarification questions in studies that
utilized face to face data collection methods
[32,34,49,50,52], but did not have this opportunity in studies that used online methods exclusively [31,35,43].
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Figure 3. Pooled estimate of awareness of PrEP among MSM in low- and middle-income countries.

Nevertheless, four studies provided useful information
regarding sources of PrEP information, noting that participants may have heard of PrEP from the internet and print
media in Malaysia and China [31,45], friends in Thailand,
Malaysia, and China [31,45,47], healthcare providers in
Thailand and Malaysia [31,47], or from previously publicized clinical trials in Peru [50].

Ayala et al. [35], 82.1% in Brazil [39], 83.3% in Kenya [51],
95.4% in Vietnam [41], and 96.2% in Peru [42]. As might be
expected, these studies were highly heterogeneous (Q statistic = 3305, I2 = 99.4; (95% CI: 99.3–99.5, p < 0.001). Metaanalysis of these studies found that 64.4% (95% CI: 53.3–
74.8) of MSM were willing to use PrEP (Figure 4).

Factors associated with willingness to use PrEP
Willingness to use PrEP
Twenty studies assessed quantitative proportions of participants who were willing to use PrEP, while two studies
reported qualitative assessment of willingness to use.
Quantitative studies reporting willingness to use PrEP
used a variety of scales and methods to derive the proportion of participants who were willing to use PrEP. Most
studies [31,33–35,37,39–41,45,47,53], used different iterations of ratings on Likert-like scales, while a few
[36,43,48,51] used simple binary measures. In general, proportions of participants willing to use PrEP varied significantly, ranging from a low proportion of 19.1% in China to a
high proportion of 96.2% in Peru. Six studies reported low
levels of willingness to use, in which less than half the
participants were willing to use PrEP. These included
19.1% and 32.1% in two Chinese studies [36,46], 36%,
39.2% to 49.2% and 41% in three Thai studies [33,43,47],
and 39.0% in Malaysia [31]. However, the majority of studies reported moderate-to-high levels of willingness to use
PrEP. In nine studies, 50–70% of participants were willing to
use PrEP, including 56.0% in Taiwan [40], 55.7% in India
[52], 62% in Myanmar [37], 63.0–91.9% in China
[44,48,49,53], and an average of 69.0% across India, Peru,
and South Africa in a multi-country study [34]. In five
studies, this proportion was >80%, and included 80.8%
among LMIC participants in the multi-country study by

Table 5 illustrates the range of factors influencing MSM’s
willingness to use PrEP documented in the included studies.
These factors, which could potentially prevent or facilitate
participants’ willingness to use of PrEP, conceptually fell
into different categories within the individual, social
(including partners, families, and communities) and structural domains (health systems and legal factors).

Individual factors
Awareness, knowledge, and information about PrEP
Awareness is an important pre-requisite of utilization of
health products, especially new interventions such as
PrEP. In most studies, initial awareness of PrEP was low.
However, once participants became aware of PrEP, most
expressed interest in using it. For instance, although none
of the participants were aware of PrEP in an Indian study by
Chakrapani et al. [52], 55.7% of them reported willing to
use it once they were informed of the concept of PrEP, its
benefits for HIV prevention, and side effects. In Myanmar
[37], 5.0% of the participants were initially aware, but
62.0% were willing to use it once they were informed
about it. In China [48], awareness was 22.0% while willingness to use after introduction of the concept to the
participants was 64.0%. In another Chinese study by Xia
et al. [45], 19.1% were initially aware, but 71.3% were
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Figure 4. Pooled estimate of willingness to use PrEP among MSM in low- and middle-income countries.

willing to use it once they became aware of it, and in yet
another Chinese study [49], 11.2% were aware of PrEP,
while 67.8% were willing to “definitely” or “probably”

take PrEP if available. The same pattern was observed in
Thailand [43], where 7.0% were aware and 36.0% were
willing to use after PrEP was described, and in Brazil

Table 5. Factors affecting willingness to use HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in lowand middle-income countries
Domains
Individual
factors

Barriers
Lack of PrEP information and
awareness.

Source study

Facilitating factors

[37,39,43,45,48,50,52] PrEP awareness and motivation to stay
HIV negative.

Source study
[32,51,52]

Concerns/doubts about PrEP

[31,32,43,44,49,52]

Perception that PrEP is 100% effective.

[50,51]

effectiveness.
Fear of side effects.

[31–33,44,49,51,52]

Need for intimacy and romance with a

[52]

partner who is HIV positive.
Low-risk perception among those at
high risk

[32,46]

Need to take medicines frequently/

[31,32,43,51]

daily.
Competing preference for condoms

[31,32,36]

Fear of HIV stigma (since ARVs are used

[49,51–53]

for treatment of HIV-positive people).
Stigma towards homosexual orientation

[32,35,50,52]

PrEP stigma or embarrassment using
Structural

PrEP.
Perceived attitudes of healthcare staff.

Convenient dosing (injectable, monthly, or

[33,50]

weekly).
Peace of mind if condom breaks or slips

[32,52]

(PrEP as a second layer of protection).

(which can also be physically felt
during sex).
Social factors

Multiple anal sex partners or history of STI [36,37,40,48]
or PEP.

[31–33,35]
[50]

factors

Ability to take PrEP pill discretely.
Desire to protect sexual partner
Peer and partner support.
Wide availability of PrEP (clinics,

[52]
[51]
[48–50,52]
[31,32,50,52]

community organizations, pharmacies,
internet, etc.)
Perceived lack of quality assurance.
Perceived lack of data confidentiality.
Cost.

[52]
[32]
[31,32,37,40,52]

Discrete packaging.
Free or heavily subsidized PrEP.

[51]
[32,37,51]
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where 61.3% were aware and 82.1% were willing to use it
[39]. In the multi-country study by Ayala et al. [35], awareness of PrEP was 69.8% while willingness to use it was
80.8% among participants from LMIC.
However, three studies were exceptions to this general
trend. In a Chinese study by Xue et al. [46], awareness was
72.8%, while willingness to use was much lower at 32.1%.
In another Chinese study by Yang et al. [47], 66.0% were
aware of PrEP, but 41.0% were willing to use it, while in the
Malaysian study by Lim et al. [31], 44.0% were aware, but
39.0% were willing to use it (Figure 5).
Motivation to stay healthy and HIV negative
Participants from Kenya identified provision of more information on PrEP as a factor that would facilitate their uptake and
utilization of PrEP as they would have known of its preventive
benefits [51]. In this study, the need to stay HIV negative and
to protect their partners were common motivators for taking
PrEP. In a typical response, one participant in a Peruvian study
[50] elaborated his understanding and the reason he would
take PrEP as about caring for his own health:
‘I [would] take PrEP, I would say that it is my own
caring about myself, something which is only mine.’
This motivation regarding the protection of one’s own health
was still sufficient even if participants had to pay for it, as
explained by another MSM participant in the same study:
‘Yes, of course [I would pay for PrEP] . . . something
that says that at least I am paying some of my own
money for my health.’
Fear of side effects
The most frequently explored determinant of potential PrEP
use was perceived side effects. In most studies, such as in

India [52], Thailand [33], Myanmar [37], Malaysia [31,32],
Kenya [51], and China [44,49], participants had concerns
about side effects, which were generally non-specific. In a
study in China [49], 44.7% of MSM participants expressed
specific worries regarding the impact of PrEP on their diet
and sleep, while in Myanmar [37], participants were more
concerned about long-term use. In the Kenyan study [51],
and in response to whether he would use PrEP, one focus
group discussion participant said that: “I will not use it,
because I don’t know if it will cause some harm in my body.”
Although concerns regarding ARV side effects reduced
willingness to use PrEP in most studies, it did not eliminate
motivations to take it entirely. In Thailand [33], concern for
side effects reduced the proportion of those willing to use
PrEP. Before participants were informed about potential side
effects, 39.2% were definitely willing to use PrEP, but 24.6%
were still willing to take PrEP once they learnt about its
possible side effects. A similar pattern was observed in the
multi-country study by Eisingerich et al. [34] as shown in the
above Table 2. In Vietnam [41], the proportion willing to use
PrEP daily reduced from 95.4% to 56.7% given side effects.

Need to adhere to PrEP
Three studies reported the requirement to take PrEP frequently as a barrier to future use of PrEP. In Thailand [43],
concerns were reported about the need for daily dose as a
potential barrier. In Kenya, participants singled out a general
dislike of medicine as a deterrent [51]. Participants in Malaysia
were aware of the need to adhere, but most admitted that
they may “lack the discipline to take PrEP on daily basis” [32].
In another Malaysian study [31], 8.3% of the 603 participants
who were not willing to use PrEP were worried about forgetting to take medication. Participants in the Thai study by
Wheelock et al. [33] suggested that monthly injection in the
arm could facilitate PrEP use by reducing the need for swallowing daily pills. In response to the question about ideal

Study, year
Ayala et al., 2013
Chakrapani et al., 2015
Draper et al., 2016
Hoagland et al., 2016
Lim et al., 2016
Sineath et al. 2013

% Aware of
PrEP

Wei et al. 2011
Xia et al., 2016

% Willing to
use PrEP

Xue et al. 2015
Yang et al., 2012
Zhang et al., 2013
Zhou et al., 2012
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Figure 5. Relationship between awareness and willingness to use PrEP in studies reporting both outcomes.
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characteristics of PrEP, one MSM participant in a study in Peru
[50] responded by saying that:
‘If they ask me to choose, I’d rather have it weekly
or twice a week, by tablet, capsule, shot or whatever, it is far more likely than doing it daily.’
However, the preference for injections was not universal in
all studies. In the multi-country study by Eisingerich et al.
[34], Indian and Peruvian MSM preferred bimonthly injection in the buttocks, while South African MSM preferred
daily pills to injection in the arm. In Vietnam [41], 27.7% of
those who were willing to use PrEP preferred a lubricant to
a pill. In contrast to the above studies, however, the
Vietnamese study did not explore preferences regarding
injectable PrEP.
Risk perception
Psychological factors such as risk perception emerged as an
important determinant of willingness to use PrEP. On the
one hand, studies by Ding et al. [36] and Zhang et al. [48]
found that MSM who had more anal sexual partners and
those who had STIs were more willing to use PrEP. In
Myanmar [37], willingness to use PrEP was higher among
participants who had more than one regular partner
(adjusted odds ratio (AOR):2.94; 95% confidence interval
(CI) = 1.41–6.14) or more than five casual partners
(AOR:2.05; 95% CI = 1.06–3.99). In this study, MSM who
never or only occasionally used condoms with casual partners were more likely to be willing to use PrEP (AOR: 2.02;
95% CI = 1.00–4.10) in Taiwan [40], willingness to use PrEP
was significantly associated with the previous receipt of HIV
PEP (AOR:3.02, 95% CI = 1.49–6.12, p = 0.002). On the
other hand, participants who perceived their risk of HIV
to be low were unlikely to use PrEP. In a Malaysian study by
Bourne et al. [32], some participants saw no need for PrEP
as they were in monogamous relationships in which they
used condoms, as they believed their risk was low. Several
of these MSM also expressed that they would consider PrEP
in the future if they would have a higher number of concurrent sexual partners. In another Malaysian study [31],
11.4% of the participants who were not willing to use PrEP
identified the fact that they always used a condom as a
reason why they would not need PrEP, implying that they
thought that their risk of HIV was low. In Taiwan, participants who had sought and used HIV non-occupational PEP
were significantly more likely to be willing to use PrEP [40].
In a Chinese study by Xue et al. [46], 54.2% of the participants did not want to use PrEP due to low self-risk assessment. In that study, 59.0% of participants perceived that
“risk behaviors were not happening every day” and therefore they would not use PrEP. This sentiment was also
reported in a Peruvian study by Galea et al. [50], where a
participant expressed the following:
‘Well, if I am a person who has continuous [sexual]
relationships yes, I’d take it, but if I [didn’t], why
would I take it?’

However, participants’ perception of risk may not have
been accurate. This lack of accurate risk perception may
contribute to the paradoxical observation that participants
in a Chinese study [48] who did not or rarely found sexual
partners on the internet were more likely to be willing to
use PrEP compared with higher-risk participants, who often
or sometimes found sexual partners on the internet.
Demographic factors
Eleven studies examined the association between willingness to use PrEP and a range of demographic factors. The
association between participants’ demographic characteristics and willingness to use PrEP was generally inconsistent.
Older age was found to be associated with willingness to
use PrEP in two studies from China [36,49] and one study
from Thailand [47]. However, this association was not found
in studies in Kenya [51], Malaysia [31], Brazil [39], Taiwan
[40], or in another study from China [48]. While two
Chinese studies [45,48] suggested that willingness to use
was higher among married participants as compared to
unmarried, divorced, or widowed participants, three other
studies from China [36,49] and Kenya [51] did not find such
association. Several studies found that income [31,49] or
employment status [31,40] were not associated with willingness to use PrEP [31]. In contrast, two Chinese studies
[48,53] found that participants with lower monthly incomes
were more willing to use it compared to those with higher
monthly incomes.
Although two studies from China and Kenya suggested
that bisexual participants were more likely to use PrEP
compared to participants who identified themselves as
homosexual [45,51], three studies in China [36,48,49] and
one study in Brazil [39] did not find such association.
Participants who had immigrated to the cities where the
studies were conducted were reported to be more willing
to use PrEP in Shanghai, China [36], but this association was
not found in another study in Beijing, China [49] or Kuala
Lumpur, Malaysia [31]. In addition, two studies examined
the impact of rural versus urban residency reported contrasting results [48,53]. In the multi-country study by Ayala
et al. [35], participants in LMIC expressed higher willingness
to use PrEP compared to those from high-income countries.
Local ethnicity was reported to be associated with willingness to use PrEP in Malaysia [31], although this was not
commonly explored across other studies. One study
reported an association between willingness to use PrEP
and depressive symptoms among Chinese participants [53],
but no other study reported association with mental health
status. Overall, the evidence was inconsistent in regards to
demographic factors.
Uncertainty regarding the benefit of PrEP
Doubts regarding the benefit of PrEP were reported in
Thailand, Malaysia, and China [32,43,44,49,52]. In China,
44.1% of participants expressed worries that PrEP had no
prevention efficacy [49]. In Malaysia [31], 9.8% feared that
PrEP would not work. Participants in qualitative studies in
Malaysia and India thought that although PrEP has been
shown to be effective in other high-income countries, it
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may not work well among local Asian MSM [32,52]. These
concerns were particularly brought to the fore given that
condoms were considered an alternative to PrEP by participants in Malaysia. In Thailand, 35% of MSM believed
condoms were more effective than PrEP and therefore
would prefer to use the former [43].
In Peru and Kenya, participants emphasized that being
confident that PrEP is effective would motivate them to use
it. A participant in a Peruvian study said: “It would have to
be 100% effective” for him to use it [50], while in Kenya, a
focus group participant stressed that: “If I am sure it is
going to work, it will motivate me to take it.” [51].
However, 44.4% of participants in Taiwan [40] were willing
to take PrEP even if it was not 100% effective, which may
be related to the high likelihood of this study’s participants
to use condoms: the majority of men willing to use PrEP
indicated that they would maintain their condom use if
taking PrEP (73.6% vs. 23.6%; p < 0.001).
Preference for condoms
Concerns of effectiveness aside, findings suggested that
some participants regarded condoms as mutually exclusive,
and in this context, some MSM preferred condoms instead
of PrEP. In Malaysia [31], 11.4% of the participants who
reported not willing to use PrEP, identified the fact that
they always use a condom as a reason why they would not
need PrEP. In another Malaysian study [32], the physical
barrier of condom was preferred to use drugs which cannot
be seen and felt. One participant in this study remarked
that “there is a physical barrier that we can see in the
condom, rather than drugs.” In the Chinese study by Ding
et al. [36], participants reporting condom use during their
last anal sex with a man were significantly less willing to
use PrEP (AOR:0.68; 95% CI = 0.47–0.97, p = 0.034), which
may be linked to preference or risk perception.
This finding is particularly relevant given that MSM participants in a Peruvian study [50], and one key informant in
an Indian study [52] were concerned that availability of
PrEP could reduce the use of condoms. One Peruvian
MSM participant, in response to a question about the
impact of PrEP, responded by saying that:
‘If you tell someone, “Look, take this pill and it will
prevent you from getting HIV,” I can assure you
that the next day, that person won’t use a condom
anymore.’
In a typical response regarding how to deal with this situation, participants in this Peruvian study suggested the need
for PrEP education to clarify if and how condoms should be
used in combination with PrEP, while emphasizing that PrEP
may not be 100% effective:
‘There should be a lot of information and say that
it is something additional to condoms and which is
going to give you some extra protection. If you tell
them that [PrEP] is 100% protective, they won’t use
[a condom] anymore.’

PrEP as a back-up plan
In Malaysia and India, there were participants who considered PrEP a complementary strategy in the context of
inconsistent condom use [52], or as a “second layer” of
protection in case condoms fail [32], or on occasions where
condom use was intended, but did not occur.
Potential resistance
One study reported concerns regarding the potential emergence of ARV drug resistance. In a Chinese study [49], 21.7%
of participants expressed worries about ARV drug resistance
from PrEP, and saw resistance as an important factor to
consider while making decision whether to use PrEP.
Need for frequent monitoring and testing
Data from two studies reported the influence that the need
for frequent clinical monitoring and HIV testing could have on
individual willingness to use PrEP. In a multi-country study by
Eisingerich et al. [34], 55.0–88.0% were willing to use PrEP
with regular HIV testing. However, a study in Thailand [43]
indicated that overall, 28.0% of participants “didn’t want to
see a doctor every three months.” In Kenya [51], a minority of
participants also reported they would not want to return for
the required regular HIV testing, and one asserted that: “I will
visit the clinic to see if it will work, but after that, if it works, I
will rarely visit clinic, will just continue to use the medicine.”

Social factors
A range of factors in family and community domains were
reported to influence willingness to use PrEP.
HIV stigma
Because similar ARV drugs are used for PrEP as for treatment
of those infected with HIV, HIV-related stigma, specifically fear
of being mistakenly identified as a person with HIV [49,51], or
being identified as a person at risk of HIV [52,53] were identified as potential barriers of the future use of PrEP. Fear of
being identified as a person at risk of HIV was particularly
prevalent in India and China [52,53]. In one Chinese study
[49], 20.1% of MSM participants expressed worries about
using PrEP for fear of being “treated as an AIDS patient by
people.” Participants from Kenya suggested that using different packaging from that used for ARV drugs for treatment of
HIV could reduce potential perceived HIV-related stigma [51].
Participants stressed that unless that was done, peers would
begin “classifying you as HIV positive.”
Stigmatization of PrEP and homosexual orientation
Apart from HIV-related stigma, three studies documented
potential stigma that can be associated with users of PrEP,
based on their assumed sexual orientation and behaviours.
In some studies, this phenomenon was referred as “PrEP
stigma” [35]. In a Malaysian study [32], some participants
felt that being on PrEP would be perceived by peers as
having a direct association with riskier behaviours such as
barebacking or using drugs during sex. In this study [32],
PrEP was linked to sex work by a participant who suggested
that PrEP use is “a money boy or go-go boy who is not in a

20

Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580

position to negotiate safe sex.” In a Peruvian study [50],
MSM were wary of accessing PrEP in neighbourhood drugstores because they were “afraid of being identified as a
person who has [homo] sexual relationships.” In an Indian
qualitative study [52], beliefs that potential PrEP users were
high-risk individuals – promiscuous, sex workers, or have
multiple sex partners – was also reported as a potential
barrier to the uptake, due to anticipated stigma. In the
multi-country study by Ayala et al. [35], PrEP stigma was
negatively correlated with willingness to use it (β: −0.51;
95% CI = − 0.55 to −0.48, p < 0.001). These themes were
further advanced by a study in Thailand [33] that explored
the extent to which participants may feel embarrassed to
use PrEP, and found that 2.7% thought that taking PrEP
would potentially be “very embarrassing” and 5.8% “fairly
embarrassing.” In another Malaysian study [31], of the
participants who reported not willing to use PrEP, 5.8%
identified concerns about “what other people might think
of me” as a reason they would not use it.
Importance of partner, peer, and family support
Data from three studies suggested that influence, reaction,
or support from partners, peers and family could either be a
barrier or facilitator of PrEP use. In an Indian qualitative
study, the possibility of covert use of PrEP not requiring
partner approval was seen as a facilitating factor [52], suggesting that some participants fear that their partners may
not be supportive. In a Chinese study [49], 14.5% of participants were worried about being refused sex by male partners after using PrEP. In a multi-country study by Eisingerich
et al. [34], proportions of participants who would definitely
want their partner or partners to know if they were taking
PrEP were 70.0% among Indian, 52.0% among Peruvian, and
68.0% among South African participants. The importance of
peer influence was reported in China [48], where the proportion willing to use PrEP increased from 64.0% to 77.0% if it
were free and also used by people known to the participants.
In Peru, the influence of peers was also documented [50]. In
a typical response characterizing other participants in the
study, one MSM reported that he would consider using PrEP
because “most of my friends were going to use it.” In this
Peruvian study [50], participants also expressed concern
regarding potential judgment from family if he was discovered to be using PrEP:
‘I think that there would be some kind of rejection
from my family. . .they would think I am a promiscuous person.’

Structural factors
Cost of PrEP
Cost emerged as an important barrier to use of PrEP in
India, China, Kenya, Malaysia, Peru, Myanmar and Taiwan.
In India, participants anticipated drugs for PrEP to be highly
priced [52]. In China, 26.3% of participants expressed worry
about not being able to afford PrEP [49]. In Malaysia,
participants suggested that PrEP should be free of charge

at the point of access, or at a reduced cost, with the
government covering the cost [31,32]. In this context [31],
8.8% of the participants who were not willing to use PrEP
identified failure to afford it as the reason they would not
use it. In the Chinese study by Zhang et al. [48], the
proportion of MSM willing to use PrEP increased from
64.0% to 71.0% if it were completely free. In Myanmar,
willingness to use PrEP was 62% as long as participants
were not required to pay for it [37]. In Peru [50], however,
participants noted that if initially provided free of charge,
users should not be required to pay for it later as that
approach may reduce its utilization:
‘If free. . .they would get used to have it for free all
the time, and when it is unavailable, they just
won’t buy it.’
In Kenya, participants in focus group discussions suggested
that they would be motivated to use PrEP if it would be
available at a subsidized cost to a price comparable to that
of condoms [51]. Subsidized or free distribution of PrEP
through community-based organizations was also identified
as a potential facilitator of PrEP uptake among lower socioeconomic status MSM in India [52].
In most studies, having to pay for PrEP reduced but did
not eliminate willingness to use it. In Malaysia, about onethird (35.6%) of participants were willing to pay out-ofpocket for PrEP, and of these, 88% were willing to pay for
it if it cost less than RM200 (USD50) per month [31]. In
Taiwan, 56.0% participants initially expressed willingness to
use PrEP, but the percentage fell to 23.0% when participants were asked if they were willing to pay an estimated
USD340 monthly for it [40]. Similarly, in Brazil [39], 75.8%
of all participants reported that they would use PrEP even if
they had to pay for it, a reduction from an overall rate of
82.1%. In a multi-country study by Eisingerich et al. [34],
39.0–88.0% of participants were willing to use PrEP despite
having to pay for it. In a Thai study [43], 65.0% of those
willing to use PrEP (36.0%) indicated they would be willing
to pay for it. In another Thai study [33], 58.8% were
“definitely” while 35.0% were “probably” willing to use
PrEP despite having to pay 500 Baht (USD15) a month for it.

Access to and attitudes of health professionals
Data from one study in Vietnam [41] indicated that previous
contact with peer health educators doubled the odds of
willingness to use PrEP (AOR: 2.28; 95% CI = 1.25–4.14,
p < 0.05). Findings from Peru emphasized the importance
of health-care professionals, especially in relation to stigmatizing attitudes [50]. In the multi-country study by Ayala et al.
[35], participants were concerned about potential stigmatizing attitudes from health providers. However, findings from
this study suggested that having experienced stigma was
positively correlated with higher willingness to use of PrEP
(β: 0.12; 95% CI = 0.02–0.23, p = 0.021), probably because
PrEP could be used without having to access healthcare
facilities for other HIV prevention services.
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Confidentiality and data protection
The fear of poor confidentiality and lack of data protection
of MSM’s identity, especially in public health facilities, was
identified as a barrier in a study in Malaysia [32], where a
participant remarked that “in the government clinic you
have to register, it has to be on record, so that’s not
discreet.” This was particularly important for participants
given stigma and cultural and religious sentiments towards
MSM in the Malaysian context.
Quality assurance of PrEP
A belief that pharmacies may distribute fake PrEP undermined trust in the quality and potency of PrEP in India [52].
Although quality can affect the effectiveness of PrEP in any
context, these concerns seemed unique to pharmaceutical
quality control systems in India, as they were absent in
other studies.
Ways to access PrEP
Several studies explored ways in which MSM wanted to
access PrEP. Venues identified for potential PrEP access
included public health facilities [31,50,52], communitybased organizations (CBOs) [31,32,52], pharmacies [31,50],
and online websites [31]. Participants’ preferences were
not consistent, but depended on their perceptions related
to stigma, data protection, and costs at each of these
venues. In India [52], some participants preferred PrEP to
be provided through government facilities as they were
concerned that if dispensed through CBOs, other MSM
might find out and label them as promiscuous. In contrast,
government facilities were viewed as likely to compromise
data confidentiality in Malaysia, and CBOs were preferred
instead [32]. MSM in Peru [50] preferred PrEP being available in healthcare centres as opposed to pharmacies, citing
higher costs. Overall, these findings suggest that increasing
ways through which PrEP can be provided could increase its
uptake, as it would cater for the needs and preferences of
different MSM.

Discussion
This review set out to determine the awareness of and
willingness to use PrEP among MSM in low-and middleincome countries. The review found that although it varies,
awareness of PrEP among MSM in low-and middle-income
countries is generally low, ranging from 0% to 72%, with a
pooled awareness of 29.7% (95% CI: 16.9–44.3) across all
studies. In contrast, willingness to use PrEP is relatively
high, ranging from 19% to 96%, with a pooled estimate of
64.4% (95% CI: 53.3–74.8). These results suggest that once
MSM become aware of PrEP, the majority are willing to
use it.
The finding of low PrEP awareness echoes that from a
previous review by Young and McDaid which showed that
MSM, sex workers, injecting drug users, and serodiscordant
participants in PrEP studies that were not part of larger
PrEP clinical research trials had limited knowledge of PrEP,
ranging from 11.0 % to 23.0 % [15]. Our review suggests

that actual awareness of PrEP may be lower than reported
in previous studies, given that participants’ understanding
of PrEP was not accurate in two studies [45,52]. This has
also been observed in studies from high-income countries.
In a US study [56] in which 62.0 % of participants had
claimed to have heard of PrEP, one-quarter were found to
have mistook PEP for PrEP.
Compared to studies in high-income settings, this review
suggests that willingness to use PrEP is relatively higher
among MSM in low-and middle-income countries. A 2012
study reported that only 28.2% of Australian MSM were
willing to use PrEP [57]. More recently, in Europe, proportions of MSM willing to use PrEP have ranged from 47.8% to
54.3% in Scotland [58,59], 57.0% in Portugal [60] and 57.6 %
in Spain [61]. Recent Canadian studies reported willingness
to use PrEP of 55.0% [62,63]. In the US where the majority of
studies on PrEP have been conducted, willingness to use
PrEP has ranged from 46.1% to 71.0% [64–69].
Nevertheless, the reported willingness to use could eventually change when PrEP is actually offered as was the case in
one Chinese study [36] included in this review, whereby 20.5%
changed their minds when PrEP was subsequently offered.
The accuracy with which willingness to use predicts actual
acceptance is difficult to determine as it could change based
on individual circumstances as well as the setting within which
PrEP is provided. For instance, the majority of MSM in openlabel extensions of RCTs show willingness to enrol, and most
go on to use it [6,70–72], although with sub-optimal adherence [71,72]. However, contexts of open-label extensions and
preceding trials differ from regular programmes in terms of
patient preparedness, education and support, and may therefore positively bias its use [15]. More realistic observations
from 20 US cities suggested that although over half of MSM
reported willing to take PrEP, only 4% actually used it [68].
Therefore, understanding the relationship between willingness to use and actual uptake of PrEP in “real-world” HIV
prevention programmes in LMIC should be prioritized in
future PrEP implementation research.
Besides the overall willingness to use PrEP, our review
provides important information regarding barriers and
motivations of its use, in response to earlier calls to
increase understanding of the context within which PrEP
might be accessed and utilized [15]. In particular, this
review identified a range of individual, social and structural
factors that may influence the willingness to use PrEP. In
the individual domain, poor knowledge about PrEP, and
doubts about its effectiveness, were common potential
barriers, alongside fear of side effects, low-risk perception
among those at high risk, and inconvenience of having to
ingest medicines daily. In addition, participants tended to
view PrEP as a competing intervention against condoms.
These findings suggest that PrEP education and information should be prioritized, including provision of accurate
information about the role of PrEP within combination HIV
prevention as recommended by WHO [4,5]. Differentiating
PrEP from PEP to potential adopters in LMIC would be
important, at least initially. Studies from high-income settings such as Spain [61] have demonstrated the importance
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of awareness in determining willingness to use PrEP. Beyond
just hearing about PrEP, the way in which PrEP information is
provided to MSM, and how well they were able to understand it, could influence their levels of willingness to use it. In
this review, some studies provided opportunities for one-toone discussions on PrEP, others provided this information
through anonymous survey, and while each has its merits,
they could influence willingness differently. Our review also
found that peers, healthcare providers, print media, and
internet websites are all useful sources of information
about PrEP for MSM. Provision of PrEP and HIV prevention
information through online and mobile dating applications
could be particularly effective in reaching MSM at higher risk
of HIV infection. This is particularly relevant given that highrisk MSM in at least two studies did not always view themselves to be at risk of HIV [32,48].
HIV risk perception and behaviours have been found to
be important determining PrEP utilization in high-income
settings [12,62,73]. Four studies in this review [36,37,40,48]
found that MSM who had more anal or casual sexual
partners, those who had received PEP, and those with a
history of STIs were more willing to use PrEP, possibly
because they had stronger perceptions of risk. A recent
review found that PrEP use was associated with STIs
among MSM [74], which underscores the need for comprehensive prevention package [75]. However in our review, it
was notable that willingness to use PrEP was high among
some participants who were at low risk e.g. those who had
one regular partner or no casual partners in Myanmar [37],
which could be due to incorrect risk perception, or bias to
use HIV prevention among MSM who were already practising safe sex behaviours. Disconnect between objective and
subjective HIV risk has also been identified in MSM from
high-income settings [76]. To address these uncertainties of
risk and optimize PrEP utilization among those at substantial risk of HIV as recommended by WHO [4,5], additional
research and programmatic tools should be devised to
assist individuals have a better self-awareness of their HIV
risk.
In addition, it is critical to continue exploring ways in
which convenient and safe PrEP can be delivered to
sidestep concerns regarding the need for frequent ingestion of drugs. Concerns regarding long-term adherence
have also been reported in the UK as a deterrent of
potential PrEP use [12]. In our review, injectable or less
frequent dosage schedules were more preferable to oral
pills [33,34,43,50]. However, user preferences are highly
contextual. In the US, a study reported that MSM preferred daily oral pills and non-visible implants over injections or visible implants, citing convenience, duration of
protection, and privacy [77]. A recent trial found that
PrEP adherence was higher in daily, compared to less
frequent time- or event-driven dosing regimens [78],
although participants in this trial were simply randomized
to these arms and didn’t have a choice. While conforming to user preferences is essential for a tailored PrEP
programme, method of delivery may have an effect on
cost, adherence, PrEP coverage per sex-act, and ultimately, “real-world” effectiveness.

A range of other individual demographic factors including
educational level, age, and residency were noted to influence
willingness to use PrEP. However, these were not universal
nor were their impacts consistent across all studies. However,
there is a need to tailor provision of PrEP to specific MSM who
are particularly at risk of HIV based on their age groups,
migration and socio-economic status and other characteristics, as part of effectively tailored combination of HIV prevention interventions. For instance, studies from the USA suggest
that PrEP can be feasibly provided to young MSM [79].
Within social and interpersonal domains, stigma was the
single most commonly encountered factor. Our review
found that MSM anticipate stigma from peers, partners,
family as well as healthcare providers and that this stigma
may be either related to HIV [49,51–53], or behaviours that
may warrant the use of PrEP [80,81], such as sex work [32]
and homosexual sex [31–33,35,50,52]. These findings suggest that it is essential to integrate strategies to mitigate
stigma related to sexual orientation as well as HIV within
PrEP programming. Chakrapani et al. suggest that community engagement may facilitate broad acceptability and
challenge stigma around PrEP [52]. Unfortunately, existing
evidence suggests that although community mobilization
and collectivization interventions can indeed mitigate
stigma [82], it is difficult to eliminate it unless these social
interventions are combined with structural interventions
and this may include decriminalization of same-sex relations in some settings.
Stigmatization in health facilities is particularly detrimental as it can prevent health seeking for other services,
suggesting that competency and skill-based training, sensitization, and performance improvement to enable provision
of friendly HIV prevention services will be required, as
argued by others [81]. The extent of partner, peer, and
family support was a significant factor affecting willingness
to use PrEP, especially in the context of stigma. Therefore,
PrEP programmes will need to ensure that consideration is
given about how partners and peers of MSM can be leveraged on to facilitate, rather than hinder, access and utilization of PrEP.
Key structural factors included perceived staff attitudes,
a lack of quality assurance, a lack of data protection and
confidentiality, and cost [31,32,37,40,50,52]. Apart from
addressing stigma and general competency to provide
MSM with PrEP among healthcare providers in LMIC –
which have been noted by others [83,84] – our results
suggest that strengthening health systems so as to assure
universal provision of high-quality PrEP, while protecting
the identities of MSM, will be critical. Strengthening drug
regulation in middle-income countries has also been highlighted as essential by other authors [85]. In this review,
cost was a common determinant of willingness to use PrEP.
Although several studies suggested thresholds at which
MSM would be willing to pay for PrEP, the studies were
conducted in diverse LMICs and socio-economic backgrounds, making it difficult to generalize thresholds.
Furthermore, most studies were conducted in cities, and
mostly in middle-, rather than low-income countries.
Nevertheless several studies [31,33,34,39,40,43,48,51]
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suggested that there were MSM in Kenya, Malaysia, Brazil,
Taiwan, Thailand, Peru, India, and South Africa who might
be motivated to use PrEP, despite having to pay full or
subsidized price for it.

Strengths and limitations of this review
Our findings build on those of previous reviews conducted by
Holt, Young, and McDaid [14,15] which focused on general
acceptability of ARV-based prevention. A unique strength of
our review is the focus on, and inclusion of, a substantially
greater number of studies from low- and middle-income
countries. Most studies in this review were Asian with relatively limited data from low- and middle-income countries in
Eastern Europe, West and North Africa, or the Caribbean
counties. However, inclusion of multi-country studies
[34,35] strengthened the generalizability of this review to
LMIC settings. In addition, the focus of the review on awareness and willingness to use realistically reflects the current
early stages of PrEP introduction in LMIC, as it excludes
acceptability which is more suited for high-income settings
where PrEP for MSM is more widely available.
The range of individual, social, and structural factors
identified in this study are likely to remain relevant even
after PrEP among MSM becomes available. Sub-optimal
uptake and retention in PrEP has been reported in the US
outside of open-label extensions [86–88] often due to similar issues identified in this review such as poor awareness
levels, cost, low risk perception, need for daily intake, and
fear of potential side effects [87–89]. Addressing these
barriers in low- and middle-income countries is particularly
relevant given that implementation of PrEP in LMIC has
lagged behind compared to high-income countries [15,16].
Rapidly scaling up access and utilization of PrEP will require
mitigating barriers while accentuating facilitators of its
potential uptake identified in this review.
We did not conduct sub-group analyses. Geographic and
socio-demographic comparisons could provide insights into
contextual determinants of awareness or willingness to use
PrEP. As noted previously, reported proportions were highly
heterogeneous. The diversity of scales and measures used
to estimate willingness to use PrEP in the included studies
may have affected the precision of our estimates, since the
observed proportions might not be entirely attributed to
sampling error, and other factors such as differences in
MSM participants and their settings could also contribute.
For this reason, we used random-effects model rather than
fixed effects model, which provides more conservative estimates e.g. wider 95% CIs, while assuming that the measurement of the parameter of interest may not be entirely
identical across studies [29]. Nevertheless, our overall findings are consistent with previous reviews which observed
high rates of willingness to use PrEP, regardless of the type
of scales used in individual studies [14,15].
Although all the included studies provided sufficient information to enable assessment of risk of bias, this was found
to be relatively high, mainly due to study designs and necessary reliance on self-reported sexual behaviour data. Survey
and interview questions related to sensitive, criminalized or

taboo sexual activities often generate inaccurate estimates
due to social desirability bias [90]. The perception of PrEP
varied both between and within studies, with its use being
seen as responsible by some participants [50] and as indicative of risky sexual behaviour by others [32,33,50,52]. Thus,
it is not possible to state with certainty the net effect of
social desirability bias on our overall findings.
Findings of this review are not generalizable beyond oral
PrEP which was the focus herein; awareness and willingness
to use other forms of PrEP might be different. Because PrEP
is frequently explored in the context of expanding combination prevention options for populations at highest risk
[4,85,91], awareness and willingness to use it could vary
based on contact with PrEP-related research and demonstration projects [81,92]. Although several databases were
searched, some studies may have been missed. Relevant
information reported in conference abstracts and non-peer
reviewed literature may have been missed as the review
only considered peer-reviewed publications to minimize
bias. While language limitations were not applied, no studies published in languages other than English and Chinese
were found. Publishing bias may still exist. Nevertheless,
this review utilized standard approaches of conducting [30]
and reporting systematic reviews [17] to minimize bias.

Conclusions
Over the last few years, RCTs have demonstrated the effectiveness of oral PrEP in reducing the risk of HIV acquisition
among MSM [9,10], demonstration projects are increasingly
being implemented [71,72,81] and the WHO has endorsed
the use of PrEP by MSM and other populations at substantial risk of HIV [4,5]. Although PrEP policies are starting to
be put into place in counties such as Malaysia, Kenya, and
South Africa, actual implementation of PrEP in low- and
middle-income countries has been relatively limited
[15,16]. In addition, criminalization of same sex relations
may limit uptake of prevention services among MSM [93].
Programmes intended to introduce or scale-up usage of
PrEP need to be based on context-specific evidence, such
as potential demand and user preferences, supported by
enabling legal and policy framework environments. This
review contributes to this evidence base by demonstrating
that despite currently low awareness of PrEP, MSM in lowand middle-income countries are willing to use it once they
become aware of it and they should be appropriately supported to deal with a range of individual, social, and structural barriers.
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